{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:44:41Z","timestamp":1760150681793,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Combining interval cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in advanced epithelial ovarian carcinoma (EOC). Although limited, growing evidence regarding carboplatin-based HIPEC highlights its potential. This retrospective study included all patients with advanced primary high-grade serous ovarian cancer who underwent interval CRS combined with carboplatin-based HIPEC at our Canadian tertiary care center between 2014 and 2020. We identified 40 patients with a median age of 61 years. The median peritoneal cancer index was 13 and complete cytoreduction was achieved in 38 patients (95%). Median hospital stay was 13 days and there were four admissions to the intensive care unit (10%) and six readmissions (15%). Severe adverse events occurred in eight patients (20%) and there was no perioperative death. Recurrence was seen in 33 patients (82%) with a median DFS of 18.0 months and a median overall survival of 36.4 months. Multivariate analyses showed that age, peritoneal cancer index, completeness of cytoreduction, occurrence of severe complications, and bowel resection did not significantly impact DFS or OS in our cohort. Interval CRS combined with carboplatin-based HIPEC for advanced primary EOC is associated with acceptable morbidity and oncological outcomes. Larger studies are required to determine the long-term outcomes.<\/jats:p>","DOI":"10.3390\/curroncol30120748","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T04:12:56Z","timestamp":1701403976000},"page":"10272-10282","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-5580","authenticated-orcid":false,"given":"Claud\u00e8le","family":"Brault","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Montreal, Montreal, QC H3T 1J4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9607-6987","authenticated-orcid":false,"given":"Alexandre","family":"Brind\u2019Amour","sequence":"additional","affiliation":[{"name":"Department of Surgery, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec, QC G1V 4G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"de Guerke","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1972-8862","authenticated-orcid":false,"given":"Marie-H\u00e9l\u00e8ne","family":"Auclair","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-4392","authenticated-orcid":false,"given":"Lucas","family":"Sideris","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika\u00ebl","family":"Soucisse","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bernard","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Royal Victoria Hospital, Montreal, QC H4A 3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Piedimonte","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Fortin","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ejso.2009.03.004","article-title":"Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer\u201412-year single center experience","volume":"35","author":"Pavlov","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.6004\/jnccn.2016.0122","article-title":"Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Morgan","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/gyno.2001.6328","article-title":"Identification of prognostic factors in advanced epithelial ovarian carcinoma","volume":"82","author":"Chi","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): Final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s002800050870","article-title":"A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer","volume":"43","author":"Steller","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20200137","DOI":"10.1515\/pp-2020-0137","article-title":"Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer","volume":"5","author":"Mikkelsen","year":"2020","journal-title":"Pleura Peritoneum"},{"key":"ref_12","first-page":"93","article-title":"Management of Epithelial Ovarian Cancer: French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. Introduction","volume":"47","author":"Lavoue","year":"2019","journal-title":"Gynecol. Obstet. Fertil. Senol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2022.02.022","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues","volume":"165","author":"Moukarzel","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/jso.25603","article-title":"Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer","volume":"120","author":"Mikkelsen","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2013.01.010","article-title":"Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: A pilot study","volume":"129","author":"Argenta","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00280-017-3376-8","article-title":"Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: A 3 year experience","volume":"80","author":"Mendivil","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13193-020-01197-1","article-title":"Phase II Trial on the Feasibility of Single-Dose Intraoperative Intraperitoneal Carboplatin in Advanced Epithelial Ovarian Cancer Following Optimal Cytoreductive Surgery","volume":"14","author":"Singh","year":"2023","journal-title":"Indian. J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2022.08.015","article-title":"HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients","volume":"167","author":"Menzies","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: Five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdx754","article-title":"OV21\/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer","volume":"29","author":"Provencher","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis","volume":"41","author":"Huo","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/02656736.2017.1293304","article-title":"Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy","volume":"33","author":"Sin","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Farrell, R., Liauw, W.S., and Morris, D.L. (2022). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: Lessons from 20 years\u2019 experience. BMC Surg., 22.","DOI":"10.1186\/s12893-022-01786-7"},{"key":"ref_28","first-page":"1467403","article-title":"Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS\/HIPEC)","volume":"2020","author":"Sardi","year":"2020","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13048-019-0509-1","article-title":"The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: The meta-analysis","volume":"12","author":"Zhang","year":"2019","journal-title":"J. Ovarian Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/12\/748\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:47Z","timestamp":1760132147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/12\/748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["curroncol30120748"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30120748","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}